Login to Your Account



Other News To Note


Wednesday, July 18, 2012
• Ipsen SA, of Paris, said partner Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., was notified that the FDA placed on hold both Phase III studies evaluating IB1001, an intravenous recombinant Factor IX therapy for the treatment and prevention of bleeding episodes in people with hemophilia B.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription